0.2898 USD
+0.01 (+3.5%)
0.2898 USD
0 (0%)
Overall VRAX gets a fundamental rating of 3 out of 10. We evaluated VRAX against 103 industry peers in the Health Care Providers & Services industry. The financial health of VRAX is average, but there are quite some concerns on its profitability. VRAX has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- VRAX had negative earnings in the past year.
- VRAX had a negative operating cash flow in the past year.
- In the past 5 years VRAX always reported negative net income.
- VRAX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -98.75%, VRAX is doing worse than 91.26% of the companies in the same industry.
- VRAX's Return On Equity of -106.24% is on the low side compared to the rest of the industry. VRAX is outperformed by 74.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.75% | ||
| ROE | -106.24% | ||
| ROIC | N/A |
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, VRAX has more shares outstanding
- VRAX has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for VRAX is higher compared to a year ago.
2.2 Solvency
- VRAX has an Altman-Z score of 1.44. This is a bad value and indicates that VRAX is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.44, VRAX is doing worse than 65.05% of the companies in the same industry.
- VRAX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.09, VRAX is doing good in the industry, outperforming 75.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.44 |
ROIC/WACCN/A
WACC10.94%
2.3 Liquidity
- VRAX has a Current Ratio of 11.35. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
- VRAX has a better Current ratio (11.35) than 98.06% of its industry peers.
- VRAX has a Quick Ratio of 11.20. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
- VRAX has a better Quick ratio (11.20) than 98.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.35 | ||
| Quick Ratio | 11.2 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 51.89% over the past year.
- Looking at the last year, VRAX shows a very negative growth in Revenue. The Revenue has decreased by -96.47% in the last year.
- The Revenue for VRAX have been decreasing by -42.47% on average. This is quite bad
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- The Revenue is expected to grow by 16.04% on average over the next years. This is quite good.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- A Price/Forward Earnings ratio of 7.10 indicates a rather cheap valuation of VRAX.
- VRAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. VRAX is cheaper than 97.09% of the companies in the same industry.
- VRAX is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.95, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.1 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- VRAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VIRAX BIOLABS GROUP LTD / VRAX FAQ
Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?
ChartMill assigns a fundamental rating of 3 / 10 to VRAX.
What is the valuation status for VRAX stock?
ChartMill assigns a valuation rating of 4 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Fairly Valued.
Can you provide the profitability details for VIRAX BIOLABS GROUP LTD?
VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.